SCHEMBL1925654

SCHEMBL1925654

CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCC(C)=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.67
ALDH1A1 P00352 5/20 0.67
PPARD Q03181 4/20 0.67
PPARA Q07869 4/20 0.67
KDM4E B2RXH2 4/20 0.67
F7 P08709 4/20 0.67
F3 P13726 4/20 0.67
FFAR1 O14842 3/20 0.67
L3MBTL1 Q9Y468 2/20 0.67
LMNA P02545 2/20 0.67
CYP3A4 P08684 2/20 0.67
CYP19A1 P11511 2/20 0.67
FABP4 P15090 2/20 0.67
HPGD P15428 2/20 0.67
ALOX15 P16050 2/20 0.67
NR4A2 P43354 2/20 0.67
HSD17B10 Q99714 2/20 0.67
TDP1 Q9NUW8 2/20 0.67
PTGS1 P23219 2/20 0.67
AKR1C3 P42330 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26461188 1.00 PPARG (0.67) PPARGALDH1A1PPARDPPARAKDM4E
SCHEMBL15908481 1.00 PPARG (0.67) PPARGALDH1A1PPARDPPARAKDM4E
SCHEMBL12261544 0.98 ALDH1A1 (0.68) PPARGALDH1A1PPARDPPARAKDM4E
SCHEMBL1784610 0.94 PPARG (0.61) PPARGALDH1A1PPARDPPARAKDM4E
SCHEMBL11502529 0.94 PPARG (0.61) PPARGALDH1A1PPARDPPARAKDM4E
SCHEMBL1784609 0.94 PPARG (0.61) PPARGALDH1A1PPARDPPARAKDM4E
SCHEMBL3670918 0.92 PPARG (0.72) PPARGALDH1A1PPARDPPARAKDM4E
SCHEMBL10740199 0.92 PPARG (0.72) PPARGALDH1A1PPARDPPARAKDM4E
SCHEMBL3670919 0.92 PPARG (0.72) PPARGALDH1A1PPARDPPARAKDM4E
SCHEMBL12629207 0.92 PPARG (0.72) PPARGALDH1A1PPARDPPARAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4321614-A1 METHOD FOR PREPARING OLIGODENDROCYTES AND USE Shenzhen Exoneuglia Biomedical Technology Co., Ltd. (CN) 2024-02-14 EP claimed
WO-2023165062-A1 METHOD FOR PREPARING OLIGODENDROCYTES AND USE 深圳市夏同生物医药科技有限公司 2023-09-07 WO claimed
CN-114262686-A Preparation method and application of oligodendrocyte 深圳市夏同生物医药科技有限公司 2022-04-01 CN claimed
US-20240226255-A9 COMPOSITIONS AND METHODS FOR ACTIVATING NK CELLS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2024-07-11 US disclosed
US-20240207212-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION UNIVERSITY OF MASSACHUSETTS 2024-06-27 US disclosed
US-20240131130-A1 COMPOSITIONS AND METHODS FOR ACTIVATING NK CELLS UNIV CALIFORNIA (US) 2024-04-25 US disclosed
EP-4321614-A1 METHOD FOR PREPARING OLIGODENDROCYTES AND USE Shenzhen Exoneuglia Biomedical Technology Co., Ltd. (CN) 2024-02-14 EP disclosed
US-11865093-B2 Methods and compositions for treating inflammation UNIVERSITY OF MASSACHUSETTS (US) 2024-01-09 US disclosed
EP-4294414-A1 COMPOSITIONS AND METHODS FOR ACTIVATING NK CELLS The Regents of The University of California (US) 2023-12-27 EP disclosed
WO-2023165062-A1 METHOD FOR PREPARING OLIGODENDROCYTES AND USE 深圳市夏同生物医药科技有限公司 2023-09-07 WO disclosed
US-20230048743-A1 Structures for Reducing Antibody-Lipase Binding GENENTECH INC. (US) 2023-02-16 US disclosed
WO-1994011370-A1 SUBSTITUTED AMINO ALKYL COMPOUNDS CELL THERAPEUTICS, INC. (US) 1994-05-26 WO disclosed
WO-1994011001-A1 HYDROXYL-CONTAINING COMPOUNDS CELL THERAPEUTICS, INC. (US) 1994-05-26 WO disclosed
WO-1994006431-A1 NOVEL EPOXIDE-CONTAINING COMPOUNDS CELL THERAPEUTICS, INC. (US) 1994-03-31 WO disclosed
EP-0584347-A1 ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS CELL THERAPEUTICS, INC. (US) 1994-03-02 EP disclosed
US-5288721-A Substituted epoxyalkyl xanthines CELL THERAPEUTICS, INC. (US) 1994-02-22 US disclosed
EP-0573617-A4 1994-02-09 EP disclosed
EP-0573617-A1 MODULATION OF CELLULAR RESPONSE TO EXTERNAL STIMULI Fred Hutchinson Cancer Research Center (US) 1993-12-15 EP disclosed
WO-1993017684-A2 ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS CELL THERAPEUTICS, INC. (US) 1993-09-16 WO disclosed
WO-1992021344-A2 MODULATION OF CELLULAR RESPONSE TO EXTERNAL STIMULI FRED HUTCHINSON CANCER RESEARCH CENTER (US) 1992-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11865093-B2 Methods and compositions for treating inflammation ABCC3, ABCC1, ABCE1 PPARG 221/4885ALDH1A1 1747/4885PPARD 901/4885
US-20240207212-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION ABCC3, ABCC1, ABCE1 PPARG 221/4885ALDH1A1 1747/4885PPARD 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.